News

German biotech firm Tacalyx snags seed funding

Berlin-based Tacalyx, a biotech company focused on the discovery and development of novel anti-TACA cancer therapies, has secured 7 million euros in seed funding. Boehringer Ingelheim Venture Fund and Kurma Partners led the round with participation from Idinvest Partners, High-Tech Gründerfonds, coparion and Creathor Ventures.

Kheiron scores $22 mln Series A

Kheiron Medical Technologies, an applied science company focused on supporting cancer diagnostics with machine learning, has raised $22 million in Series A funding. Atomico led the round with participation from Connect Ventures, Greycroft, Hoxton Ventures and EXOR Seeds. As part of this investment, Atomico Principal Irina Haivas will join Kheiron's board.

iGan appoints new CFO/COO

Canadian healthcare technology venture firm iGan Partners has named Mark Bhattacharya as its new chief financial officer and chief operating officer. Previously, he worked at Morneau Shepell Asset and Risk Management Ltd where he was head of operations and chief compliance officer. Last year, iGan closed its debut fund at $100 million.

Nview Health rakes in $4.65 mln

Atlanta-based Nview Health, a behavioral health solutions company, has secured $4.65 million in funding. The backer was BIP Capital.

Biotech startup A-Alpha Bio nets $2.8 mln

Seattle-based A-Alpha Bio, a biotechnology startup, has raised $2.8 million in funding. OS Fund led the round with participation from other investors that included AME Cloud Ventures, Boom Capital, Madrona Venture Group, Sahsen Ventures and Washington Research Foundation.

VC-backed Artios appoints chief business officer

UK-based Artios Pharma Limited, a DNA damage response company developing treatments for cancer, has named Tania Dimitrova as chief business officer. Previously, she worked at Pfizer Inc where she was a director in worldwide business development. Artios is backed by Arix Bioscience plc, SV Health Investors, M Ventures, IP Group plc, AbbVie Ventures, Andera Partners, LSP, Pfizer Ventures and Novartis Venture Fund.

Amphivena Therapeutics lands $62 mln Series C

South San Francisco-based Amphivena Therapeutics Inc, a developer of T cell engager therapeutics for cancer, has raised $62 million in Series C financing. NanoDimension and Qiming Venture Partners USA led the round.

French medical device firm FeetMe snags Series A

Paris-based FeetMe, a medical device company, has raised 9.4 million euros in Series A funding. LBO France led the round with participation from Kurma Diagnostics, Paris Saclay seed fund, Idinvest Partners, Seventure and SOSV.

Cyber insurance comes to the rescue when security fails

Panache Ventures raises C$58 mln for maiden fund

Panache Ventures, a seed-stage venture firm, has closed its debut fund at C$58 million, beating its initial $40 million target. The fund's investors include Alberta Enterprise Corporation, Fonds de solidarité FTQ, Investissement Québec, National Bank of Canada, TELUS Ventures, BMO Bank of Montreal and BC Tech Fund, managed by Kensington Capital. In March 2018, Panache announced it had raised C$25 million in the first close of the fund. Panache has offices in Montreal, Toronto, Calgary and Vancouver.